

### **Disclosure Slide**

Financial Disclosure for: Omer Weissbrod

I have nothing to disclose








## Leveraging fine-mapping and non-European training data to improve trans-ethnic polygenic risk scores

Omer Weissbrod Alkes Price Group Harvard School of Public Health





## Polygenic risk scores lose accuracy in ASHO non-European target populations



Martin et al. 2019 Nat Genet








### Introduction:

Why do polygenic risk scores lose accuracy across populations?

### > Methods










### Introduction: Why do polygenic risk scores lose accuracy across populations?

### Methods





## Why do polygenic risk scores lose accuracy across populations?




1. LD differences

2. Allele frequency differences

Marquez-Luna *et al.* 2017 Genet Epidem. Duncan et al. 2019 Nat Commun. Martin *et al.* 2019 Nat Genet Wang *et al.* 2020 Nat Commun.






# Why do polygenic risk scores lose accuracy across populations?




1. LD differences

(when using non-causal SNPs to predict)

2. Allele frequency differences








# Why do polygenic risk scores lose accuracy across populations?




LD differences
(when using non-causal SNPs to predict)

2. Allele frequency differences (even when using causal SNPs)







## Two strategies to mitigate loss of polygenic risk score accuracy



**1. LD differences** 

(when using non-causal SNPs to predict)

Predict using <u>causal</u> SNPs (fine-mapping)

2. Allele frequency differences (even when using causal SNPs) Combine data from Europeans and non-Europeans










### Introduction:

Why do polygenic risk scores lose accuracy across populations?

### > Methods







- Estimate effect sizes for **all** SNPs
- $\beta_i$  represents a **causal** effect

- Estimate effect sizes for a subset of SNPs
- $\beta_i$  represents a **causal+tagging** effect






### PolyPred combines a standard PRS with a fine-mapping PRS (accounts for LD differences)



#### from target cohort (N>100)

Standard PRS: BOLT-LMM (Loh *et al.* 2015a Nat Genet, 2018) SBayesR (Lloyd-Jones *et al.* 2019 Nat Commun)

Fine-mapping PRS: PolyFun + SuSiE **ASF** (Weissbrod *et al.* accepted in principle Nat Genet













### Introduction:


Why do polygenic risk scores lose accuracy across populations?

### > Methods















### Conclusions



- PolyPred leverages fine-mapping to improve trans-ethnic PRS (32% improvement vs BOLT in UKB Africans, 11% improvement vs. BOLT in UKB East Asians)
- PolyPred+ leverages fine-mapping and non-European data (24% improvement vs BOLT in UKB East Asians)





### Acknowledgements





Alkes Price Huwenbo Shi Steven Gazal Wouter Peyrot Price Group



Masahiro Kanai

Alicia Martin Hilary Finucane Amit Khera Yukinori Okada



*biobank*\*\*

